Can we select NSCLC patients for immune checkpoint therapy?
|
Número de diapositiva 1 |
1 |
|
Número de diapositiva 2 |
2 |
|
Número de diapositiva 3 |
3 |
|
Who (not) to give? |
4 |
|
Who to give? |
5 |
|
PD-L1 as a biomarker in NSCLC |
6 |
|
Número de diapositiva 7 |
7 |
|
Comparison of PD-L1 assays in NSCLC |
8 |
|
Número de diapositiva 9 |
9 |
|
Second-Line IO: Does PD-L1 worth? |
10 |
|
Second-Line IO: Does PD-L1 worth? |
11 |
|
Should we treat PDL1 neg NSCLC |
12 |
|
1st L IO+CT: Does PDL1 worth? |
13 |
|
1st L IO+CT: Does PDL1 worth? |
14 |
|
Tumor mutational burden |
15 |
|
Número de diapositiva 16 |
16 |
|
Tumor mutational burden |
17 |
|
Número de diapositiva 18 |
18 |
|
TMB in prospective trial |
19 |
|
New treatment paradigm in NSCLC |
20 |
|
Immunotherapy in EGFR-mutant |
21 |
|
Número de diapositiva 22 |
22 |
|
MSI and ICI efficacy |
23 |
|
LIPI: Lung Immune Prognosis Index |
24 |
|
ICI in a real population |
25 |
|
Who (not) to give? |
26 |
|
Age and ICI efficacy |
27 |
|
Age and ICI efficacy |
28 |
|
Baseline autoimmune disorders in NSCLC |
29 |
|
ICI in patients with baseline autoimmune diseases |
30 |
|
Baseline steroids and ICI |
31 |
|
PS ≥ 2 and ICI efficacy |
32 |
|
Unrepresented population: CA209-817 |
33 |
|
Who (not) to give? |
34 |
|
Common Pattern? |
35 |
|
Early deaths (<3 mo.): characteristics |
36 |
|
Hyperprogressive disease |
37 |
|
Conclusions |
38 |